
## Julian R Levell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5349313/publications.pdf Version: 2024-02-01



IIIIIAN RIEVELL

#	Article	IF	CITATIONS
1	Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activity. Journal of Biological Chemistry, 2021, 296, 100349.	3.4	8
2	Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 1213-1220.	2.8	17
3	Practical Applications of Deep Learning To Impute Heterogeneous Drug Discovery Data. Journal of Chemical Information and Modeling, 2020, 60, 2848-2857.	5.4	35
4	Early Drugâ€Discovery Efforts towards the Identification of EP300/CBP Histone Acetyltransferase (HAT) Inhibitors. ChemMedChem, 2020, 15, 955-960.	3.2	13
5	Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time. ACS Medicinal Chemistry Letters, 2020, 11, 1205-1212.	2.8	24
6	Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300/CBP Histone Acetyltransferase Inhibitor. ACS Medicinal Chemistry Letters, 2020, 11, 1324-1329.	2.8	43
7	Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors. ACS Medicinal Chemistry Letters, 2018, 9, 746-751.	2.8	11
8	Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity. Structure, 2017, 25, 506-513.	3.3	53
9	Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1. ACS Medicinal Chemistry Letters, 2017, 8, 151-156.	2.8	35
10	Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. ACS Medicinal Chemistry Letters, 2017, 8, 1116-1121.	2.8	84